Ras inhibitors with a tricyclic core

TW202639558APending Publication Date: 2026-10-01ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115103751
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-01-31
Filing Date
2026-01-30
Publication Date
2026-10-01
Patent Text Reader

Abstract

The present specification relates to compounds, and pharmaceutically acceptable salts thereof, that inhibit the growth of cancers that express G13D mutant Ras proteins. The molecules of the specification are thus indicated for use in the treatment of Ras G13D mutant cancers and for use in methods for the treatment of Ras G13D mutant cancers.
Need to check novelty before this filing date? Find Prior Art